Aptorum Group Ltd Class A
$ 0.81
1.28%
24 Feb - close price
- Market Cap 6,589,900 USD
- Current Price $ 0.81
- High / Low $ 0.83 / 0.77
- Stock P/E N/A
- Book Value 3.15
- EPS -0.31
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.14 %
- 52 Week High 4.47
- 52 Week Low 0.65
About
Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$80.00
Quarterly Earnings
| Sep 2025 | Mar 2025 | Sep 2024 | Mar 2023 | Jun 2022 | Mar 2022 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-18 | 2025-04-30 | 2024-12-20 | 2023-04-28 | 2022-09-30 | 2022-04-29 | 2021-09-15 | 2021-04-19 | 2021-03-31 | 2020-12-31 | 2020-09-01 | 2020-04-29 |
| Reported EPS | -0.06 | -0.29 | -0.5 | -2.22 | -0.05 | -0.25 | -0.47 | 0.38 | -0.2346 | 0.1889 | -0.21 | -0.33 |
| Estimated EPS | None | 0 | 0 | None | -3 | -3.3 | -3 | -3.1 | 0 | 0 | 0 | 0 |
| Surprise | 0 | -0.29 | -0.5 | 0 | 2.95 | 3.05 | 2.53 | 3.48 | -0.2346 | 0.1889 | -0.21 | -0.33 |
| Surprise Percentage | None% | None% | None% | None% | 98.3333% | 92.4242% | 84.3333% | 112.2581% | None% | None% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APM
2026-02-02 12:57:49
Aptorum Group announced a collaboration between its subsidiary DiamiR Biosciences and Instant NanoBiosensors (INB) to validate INB's automated APOE testing platform for Alzheimer’s disease risk assessment. This validation will occur in DiamiR's CLIA-certified and CAP-accredited laboratory, comparing INB's G8 Genotyping Analyzer to DiamiR's New York State approved APOE test. The goal is to evaluate the platform's performance, clinical suitability, and potential to enhance testing throughput for Alzheimer's disease diagnosis.
2026-02-01 20:57:43
Aptorum Group, DiamiR Biosciences, and Instant NanoBiosensors (INB) have announced a collaboration for DiamiR to validate INB’s automated APOE testing platform for Alzheimer’s disease. DiamiR will compare INB’s G8 Genotyping Analyzer against its New York State approved APOE test within its CLIA-certified, CAP-accredited laboratory. This initiative aims to enhance Alzheimer’s disease risk assessment capabilities and laboratory throughput, building on the upcoming merger between Aptorum Group and DiamiR Biosciences.
2025-11-02 11:40:18
DiamiR Biosciences and Aptorum Group announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This approval allows DiamiR to offer its validated APOE Genotyping molecular testing in various biological samples through its CLIA-certified and CAP-accredited clinical laboratory to licensed healthcare providers in New York State and nationwide. The milestone enhances diagnostics capabilities for the merging companies.
2025-10-26 05:02:20
Aptorum Group Limited announced its intention to acquire URF Holding Group Limited, a company focused on urban revitalization in China, through a non-binding Letter of Intent and Term Sheet. The acquisition, which involves a reverse takeover, will result in Aptorum distributing its existing businesses to pre-acquisition shareholders. U Group's strategy targets China's "Generation Z" consumption growth through curated shopping experiences and community rejuvenation, with significant revenues reported for 2020 and 2021.
2025-10-26 05:02:20
Aptorum Group Limited announced the completion of a private offering of a $3 million convertible note due in December 2023. The note was solely subscribed by Aenco Technologies Limited, an entity indirectly owned by Aptorum's Non-Executive Director and major shareholder, Mr. Ian Huen. Proceeds will fund research and development of therapeutic candidates, its liquid biopsy diagnostics program, commercialization of NativusWell®, and general corporate purposes.
2025-10-26 05:02:20
YOOV Group Holding Limited has cancelled its acquisition of Aptorum Group Limited in a reverse merger transaction that was initially announced on March 1, 2024. The deal, valued at $250 million, would have resulted in YOOV shareholders owning approximately 90% of the combined company. As part of the termination agreement, YOOV is required to reimburse Aptorum for 90% of incurred expenses, up to $1,000,000.
